AC Immune (ACIU) said Thursday it plans to cut its workforce by around 30% as it moves to extend its cash runway and focus investments on most important assets, including three clinical-stage active immunotherapy programs.
The moves follow the executive management's strategic review and are estimated to extend the company's cash resources, which stood at 127.1 million Swiss francs ($158 million) as of June 30, through the end of Q3 2027.
AC Immune said expects to complete the job cuts by the end of 2025 and the cost reductions to be fully effective early next year.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments